001     164016
005     20240722102836.0
024 7 _ |a pmc:PMC9232883
|2 pmc
024 7 _ |a 10.1002/mds.28959
|2 doi
024 7 _ |a pmid:35150594
|2 pmid
024 7 _ |a 0885-3185
|2 ISSN
024 7 _ |a 1531-8257
|2 ISSN
024 7 _ |a altmetric:122968845
|2 altmetric
037 _ _ |a DZNE-2022-00679
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Van de Vondel, Liedewei
|0 0000-0003-2214-5908
|b 0
245 _ _ |a De Novo and Dominantly Inherited SPTAN1 Mutations Cause Spastic Paraplegia and Cerebellar Ataxia.
260 _ _ |a New York, NY
|c 2022
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1721636898_12033
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Pathogenic variants in SPTAN1 have been linked to a remarkably broad phenotypical spectrum. Clinical presentations include epileptic syndromes, intellectual disability, and hereditary motor neuropathy.We investigated the role of SPTAN1 variants in rare neurological disorders such as ataxia and spastic paraplegia.We screened 10,000 NGS datasets across two international consortia and one local database, indicative of the level of international collaboration currently required to identify genes causative for rare disease. We performed in silico modeling of the identified SPTAN1 variants.We describe 22 patients from 14 families with five novel SPTAN1 variants. Of six patients with cerebellar ataxia, four carry a de novo SPTAN1 variant and two show a sporadic inheritance. In this group, one variant (p.Lys2083del) is recurrent in four patients. Two patients have novel de novo missense mutations (p.Arg1098Cys, p.Arg1624Cys) associated with cerebellar ataxia, in one patient accompanied by intellectual disability and epilepsy. We furthermore report a recurrent missense mutation (p.Arg19Trp) in 15 patients with spastic paraplegia from seven families with a dominant inheritance pattern in four and a de novo origin in one case. One further patient carrying a de novo missense mutation (p.Gln2205Pro) has a complex spastic ataxic phenotype. Through protein modeling we show that mutated amino acids are located at crucial interlinking positions, interconnecting the three-helix bundle of a spectrin repeat.We show that SPTAN1 is a relevant candidate gene for ataxia and spastic paraplegia. We suggest that for the mutations identified in this study, disruption of the interlinking of spectrin helices could be a key feature of the pathomechanism. © 2022 International Parkinson and Movement Disorder Society.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a ataxia
|2 Other
650 _ 7 |a next-generation sequencing
|2 Other
650 _ 7 |a rare diseases
|2 Other
650 _ 7 |a spastic paraplegia
|2 Other
650 _ 7 |a spectrin
|2 Other
650 _ 2 |a Carrier Proteins: genetics
|2 MeSH
650 _ 2 |a Cerebellar Ataxia: genetics
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Intellectual Disability: genetics
|2 MeSH
650 _ 2 |a Microfilament Proteins: genetics
|2 MeSH
650 _ 2 |a Mutation: genetics
|2 MeSH
650 _ 2 |a Paraplegia: genetics
|2 MeSH
650 _ 2 |a Pedigree
|2 MeSH
650 _ 2 |a Phenotype
|2 MeSH
650 _ 2 |a Spastic Paraplegia, Hereditary: genetics
|2 MeSH
650 _ 2 |a Spectrin: genetics
|2 MeSH
700 1 _ |a De Winter, Jonathan
|b 1
700 1 _ |a Beijer, Danique
|b 2
700 1 _ |a Coarelli, Giulia
|b 3
700 1 _ |a Wayand, Melanie
|0 P:(DE-2719)9001023
|b 4
|u dzne
700 1 _ |a Palvadeau, Robin
|0 0000-0002-4730-6598
|b 5
700 1 _ |a Pauly, Martje G
|0 0000-0002-7794-0282
|b 6
700 1 _ |a Klein, Katrin
|b 7
700 1 _ |a Rautenberg, Maren
|b 8
700 1 _ |a Guillot-Noël, Léna
|b 9
700 1 _ |a Deconinck, Tine
|b 10
700 1 _ |a Vural, Atay
|b 11
700 1 _ |a Ertan, Sibel
|b 12
700 1 _ |a Dogu, Okan
|b 13
700 1 _ |a Uysal, Hilmi
|0 0000-0002-6063-377X
|b 14
700 1 _ |a Brankovic, Vesna
|b 15
700 1 _ |a Herzog, Rebecca
|0 0000-0002-5906-5947
|b 16
700 1 _ |a Brice, Alexis
|b 17
700 1 _ |a Dürr, Alexandra
|0 P:(DE-2719)9000429
|b 18
|u dzne
700 1 _ |a Klebe, Stephan
|b 19
700 1 _ |a Stock, Friedrich
|b 20
700 1 _ |a Bischoff, Almut Turid
|b 21
700 1 _ |a Rattay, Tim W
|0 P:(DE-2719)2811827
|b 22
|u dzne
700 1 _ |a Sobrido, María-Jesús
|0 0000-0002-6411-1020
|b 23
700 1 _ |a De Michele, Giovanna
|b 24
700 1 _ |a De Jonghe, Peter
|b 25
700 1 _ |a Klopstock, Thomas
|0 P:(DE-2719)2810704
|b 26
|u dzne
700 1 _ |a Lohmann, Katja
|0 P:(DE-2719)9000191
|b 27
|u dzne
700 1 _ |a Zanni, Ginevra
|b 28
700 1 _ |a Santorelli, Filippo M
|b 29
700 1 _ |a Timmerman, Vincent
|b 30
700 1 _ |a Haack, Tobias B
|b 31
700 1 _ |a Züchner, Stephan
|b 32
700 1 _ |a Consortium, PREPARE
|b 33
|e Collaboration Author
700 1 _ |a Schüle, Rebecca
|0 P:(DE-2719)2812018
|b 34
|u dzne
700 1 _ |a Stevanin, Giovanni
|b 35
700 1 _ |a Synofzik, Matthis
|0 P:(DE-2719)2811275
|b 36
|u dzne
700 1 _ |a Basak, A Nazli
|0 0000-0001-6977-2517
|b 37
700 1 _ |a Baets, Jonathan
|b 38
773 _ _ |a 10.1002/mds.28959
|g p. mds.28959
|0 PERI:(DE-600)2041249-6
|n 6
|p 1175-1186
|t Movement disorders
|v 37
|y 2022
|x 0885-3185
856 4 _ |u https://pub.dzne.de/record/164016/files/DZNE-2022-00679_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/164016/files/DZNE-2022-00679_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:pub.dzne.de:164016
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)9001023
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 18
|6 P:(DE-2719)9000429
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 22
|6 P:(DE-2719)2811827
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 26
|6 P:(DE-2719)2810704
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 27
|6 P:(DE-2719)9000191
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 34
|6 P:(DE-2719)2812018
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 36
|6 P:(DE-2719)2811275
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2022
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2021-01-30
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-30
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-30
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2022-11-11
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOVEMENT DISORD : 2021
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-11
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-11
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b MOVEMENT DISORD : 2021
|d 2022-11-11
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 0
920 1 _ |0 I:(DE-2719)1240005
|k Core ICRU
|l Core ICRU
|x 1
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1210000
980 _ _ |a I:(DE-2719)1240005
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21